GENE ONLINE|News &
November 8, 2012: Completion of the Liver Cancer Genome
CellTech Innovation Accelerator CEO, James Tsai (front left), and Cyto-Facto Inc. CEO, Shin Kawamata (front right), signed a memorandum of understanding (MOU), fostering collaborative APAC industry efforts.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. The whole genome sequence of HCC was completed by RIKEN, a Japanese research institution, and was published on November 8, 2012. The result revealed many new cancer-associated genes, a variety of genomic alterations, and the common integration sites for hepatitis B virus (HBV) genome. The report was a step forward for studying the HBV virus and for developing new drugs for liver cancer.
Reference
https://www.ncbi.nlm.nih.gov/pubmed/23142287
©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Author
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
